CTOs on the Move

RxAdvance

www.rxadvance.com

 
RxAdvance, a national full service PBM, leverages the disruptive Collaborative PBM Cloud™ to manage standard and specialty drug benefits with unmatched regulatory compliance and transparency. In addition, RxAdvance is willing to share global pharmacy risk, avoidable drug-impacted medical risk, and bundled episode specialty pharmacy risk, standing shoulder-to-shoulder with plan sponsors as a true accountable partner. This risk model has never been offered by any other PBM.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.rxadvance.com
  • 2 Park Central Drive
    Southborough, MA USA 01772
  • Phone: 508.804.6900

Executives

Name Title Contact Details
Bijendra Malik
 Chief Information Security Officer Profile

Similar Companies

Forefront Dermatology

Forefront Dermatology is a leading dermatology group practice with numerous convenient locations throughout the United States. Find a dermatologist near me today.

PharmaLeaders

PharmaLeaders is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Groupe Essaim

Groupe Essaim Inc. is a Boucherville, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Luitpold Pharmaceuticals

At Luitpold Animal Health, we are totally committed to advancing the cause of better animal health.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.